Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo Sells 1,343 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo sold 1,343 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $11.38, for a total transaction of $15,283.34. Following the completion of the sale, the senior vice president now directly owns 122,330 shares of the company’s stock, valued at approximately $1,392,115.40. This trade represents a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $11.88 on Friday. Dyne Therapeutics, Inc. has a fifty-two week low of $11.18 and a fifty-two week high of $47.45. The company has a 50 day moving average price of $15.10 and a 200 day moving average price of $25.73. The stock has a market capitalization of $1.34 billion, a P/E ratio of -3.34 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. On average, research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on DYN. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Royal Bank of Canada restated an “outperform” rating and set a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. BMO Capital Markets assumed coverage on Dyne Therapeutics in a report on Wednesday. They issued an “outperform” rating and a $50.00 price target on the stock. Scotiabank started coverage on Dyne Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective for the company. Finally, HC Wainwright dropped their price objective on Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $48.85.

Hedge Funds Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in DYN. Quantbot Technologies LP purchased a new stake in shares of Dyne Therapeutics during the third quarter worth approximately $34,000. Point72 DIFC Ltd acquired a new position in Dyne Therapeutics during the 3rd quarter worth approximately $36,000. US Bancorp DE increased its position in shares of Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Dyne Therapeutics in the 4th quarter valued at $50,000. Finally, KBC Group NV lifted its position in shares of Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after purchasing an additional 978 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.